Jonathan E Rosenberg

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
    Jonathan E Rosenberg
    University of California at San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Prostate Cancer 3:122-4. 2004
  2. doi request reprint Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    J E Rosenberg
    Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
    Ann Oncol 19:946-50. 2008
  3. ncbi request reprint Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Jonathan E Rosenberg
    UCSF Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 7:1729-36. 2007
  4. ncbi request reprint Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
    Jonathan E Rosenberg
    Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 110:556-63. 2007
  5. ncbi request reprint Update on chemotherapy for advanced bladder cancer
    Jonathan E Rosenberg
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    J Urol 174:14-20. 2005
  6. ncbi request reprint A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
    Jonathan E Rosenberg
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Cancer 103:2035-41. 2005
  7. ncbi request reprint A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
  8. ncbi request reprint Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium
    Andrea L Harzstark
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
    Cancer 117:2419-25. 2011
  9. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
  10. pmc Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009

Detail Information

Publications18

  1. ncbi request reprint Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
    Jonathan E Rosenberg
    University of California at San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Prostate Cancer 3:122-4. 2004
    ..Finding new agents that are active in the second-line setting and identifying relevant outcome variables and predictive pretreatment variables are crucial in improving survival and quality of life for this patient population...
  2. doi request reprint Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    J E Rosenberg
    Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
    Ann Oncol 19:946-50. 2008
    ..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC...
  3. ncbi request reprint Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Jonathan E Rosenberg
    UCSF Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 7:1729-36. 2007
    ..Neoadjuvant strategies are a potent tool for research and should be employed to test new agents for the treatment of transitional cell carcinoma...
  4. ncbi request reprint Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
    Jonathan E Rosenberg
    Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 110:556-63. 2007
    ..This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC)...
  5. ncbi request reprint Update on chemotherapy for advanced bladder cancer
    Jonathan E Rosenberg
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    J Urol 174:14-20. 2005
    ..Recent years have seen several advances in the treatment of locally advanced and metastatic bladder cancer. We summarize the current state of the art for advanced bladder cancer treatment...
  6. ncbi request reprint A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
    Jonathan E Rosenberg
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Cancer 103:2035-41. 2005
    ..R115777 is a potent farnesyl transferase inhibitor and has significant antitumor effects in vitro and in vivo...
  7. ncbi request reprint A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...
  8. ncbi request reprint Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium
    Andrea L Harzstark
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
    Cancer 117:2419-25. 2011
    ..Phase 1 testing determined the maximum tolerated dose and dose-limiting toxicities with the combination regimen; a phase 2 study was conducted to evaluate the activity of the combination...
  9. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
    ..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models...
  10. pmc Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
    ..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed...
  11. doi request reprint A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
    ....
  12. pmc Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
    ..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy...
  13. ncbi request reprint Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer
    Jorge A Garcia
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    BJU Int 99:519-24. 2007
    ....
  14. doi request reprint Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB, AL, USA
    Crit Rev Oncol Hematol 87:80-9. 2013
    ..85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found...
  15. pmc A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
    Amy J Chien
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:5569-75. 2009
    ..This study investigates the clinical relevance of this approach...
  16. ncbi request reprint A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ..East Hanover, NJ, USA), as measured by prostate-specific antigen (PSA) kinetics in men with biochemical relapse of prostate cancer after definitive local therapy...
  17. doi request reprint Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  18. ncbi request reprint Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, OH 44195, USA
    Clin Genitourin Cancer 5:232-4. 2006
    ..Herein, we report 2 cases of patients with cytokine-refractory metastatic RCC who received sunitinib and achieved sufficient decrease in tumor burden to permit subsequent surgical resection, resulting in long-term CR...